Organisation: Amgen

How to navigate the biosimilar and biologic markets amid challenging US litigation trends

Featured in The Guide to Life Sciences: Key issues for senior life sciences executives 2024

A slew of recent litigation in the biologics and biosimilars space has drastically changed the landscape of this space and made it more challenging for biopharma companies and IP professionals.

24 June 2024

Alexion and Novartis/Genentech start UPC’s first ever biosimilar disputes

The patentees join Amgen as the only pharma companies yet to use the pan-European court

24 April 2024

A guide to ongoing biosimilar battles as Johnson & Johnson reaches Stelara settlement

IAM hones in on spats over several biologic drugs in Europe and beyond

08 April 2024

UPC Court of Appeal hears crucial transparency test case

IAM speaks to both sides following landmark document access hearing

12 March 2024

NPEs at the UPC; nChain licensing ambitions; European Parliament adopts SEP regulation; 3GPP declarations; GenAI patent study; plus much more

Get ready for the new working week with a summary of all the stories posted on the IAM platform over the past seven days

03 March 2024

Amgen’s UPC battles could bring consolation at the end of decade-long PCSK9 war

The company will be looking to make up for the terrible reversal of fortunes it has suffered in long-running spat with Sanofi and Regeneron

29 February 2024

mRNA firms and other biopharma patentees dominate ‘Innovation Momentum’ rankings

Newly released report throws light on which life sciences companies have the most dynamic IP portfolios

22 February 2024

How courts around the world are tackling AI, SEPs and software eligibility

Litigation from Australia, India, Colombia and Europe illustrates the pivotal role played by the courts, especially in the most volatile areas of patent law

19 February 2024

YMTC on IP independence; General Motors joins Avanci 5G; Lenovo’s new SEP litigation tactics; InterDigital’s AI focus; Apple v Rivos; plus much more

Get ready for the new working week with a summary of all the stories posted on the IAM platform over the past seven days

18 February 2024

Alexion injunction against Amgen overturned in landmark Munich appeal

Reversal has major implications for future disputes involving rare disease treatments

12 February 2024